1 – 27 of 27
- show: 50
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2020
-
Mark
Human G-MDSCs are neutrophils at distinct maturation stages promoting tumor growth in breast cancer
(
- Contribution to journal › Article
- 2016
-
Mark
ANLN is a prognostic biomarker independent of Ki-67 and essential for cell cycle progression in primary breast cancer
(
- Contribution to journal › Article
- 2014
-
Mark
Abstract P2-10-28: The Prognostic Index, KiGE, Combining Proliferation, Histological Grade and Estrogen Receptor Status Challenges Gene Profiling – A Study in 1,854 Chemo-Naïve Women with N0/N1 Primary Breast Cancer.
(
- Contribution to journal › Published meeting abstract
- 2013
-
Mark
Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial.
(
- Contribution to journal › Article
-
Mark
The combination of Ki67, histological grade and estrogen receptor status identifies a low-risk group among 1,854 chemo-naïve women with N0/N1 primary breast cancer.
(
- Contribution to journal › Article
- 2012
-
Mark
Low ERK Phosphorylation in Cancer-Associated Fibroblasts Is Associated with Tamoxifen Resistance in Pre-Menopausal Breast Cancer
(
- Contribution to journal › Article
-
Mark
The cocaine- and amphetamine-regulated transcript mediates ligand-independent activation of ER alpha, and is an independent prognostic factor in node-negative breast cancer
(
- Contribution to journal › Article
- 2011
-
Mark
Stromal Expression of β-Arrestin-1 Predicts Clinical Outcome and Tamoxifen Response in Breast Cancer.
(
- Contribution to journal › Article
-
Mark
Tumor-specific HMG-CoA reductase expression in primary premenopausal breast cancer predicts response to tamoxifen.
(
- Contribution to journal › Article
-
Mark
A non-functional retinoblastoma tumor suppressor (RB) pathway in premenopausal breast cancer is associated with resistance to tamoxifen.
(
- Contribution to journal › Article
- 2010
-
Mark
STROMA-DERIVED MARKERS PREDICTING BREAST CANCER PROGNOSIS AND TREATMENT RESPONSE
(
- Contribution to journal › Published meeting abstract
-
Mark
Epidermal growth factor receptor and vascular endothelial growth factor receptor 2 are specific biomarkers in triple-negative breast cancer. Results from a controlled randomized trial with long-term follow-up.
(
- Contribution to journal › Article
-
Mark
Modeling Prognostic Markers in Breast Cancer — Are We Using Them the Optimal Way?
(
- Contribution to journal › Published meeting abstract
- 2009
-
Mark
Vascular endothelial growth factor receptor 2 is a significant negative prognostic biomarker in triple-negative breast cancer: results from a controlled randomised trial of premenopausal breast cancer
(
- Contribution to journal › Published meeting abstract
-
Mark
Nuclear expression of the RNA-binding protein RBM3 is associated with an improved clinical outcome in breast cancer.
2009) In Modern Pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 22. p.1564-1574(
- Contribution to journal › Article
-
Mark
Erythropoietin Receptor Expression and Correlation to Tamoxifen Response and Prognosis in Breast Cancer.
(
- Contribution to journal › Article
- 2008
-
Mark
Prognostic impact of tumour-specific HMG-CoA reductase expression in primary breast cancer
(
- Contribution to journal › Article
- 2007
-
Mark
Quantitative measurement of epidermal growth factor receptor is a negative predictive factor for tamoxifen response in hormone receptor - Positive premenopausal breast cancer
(
- Contribution to journal › Article
- 2006
-
Mark
Hypoxia inducible factor-1alpha is a prognostic marker in premenopausal patients with intermediate to highly differentiated breast cancer but not a predictive marker for tamoxifen response.
(
- Contribution to journal › Article
-
Mark
Classification of breast cancer using genetic algorithms and tissue microarrays
(
- Contribution to journal › Article
-
Mark
CA IX is an independent prognostic marker in premenopausal breast cancer patients with one to three positive lymph nodes and a putative marker of radiation resistance
(
- Contribution to journal › Article
-
Mark
High progesterone receptor expression correlates to the effect of adjuvant tamoxifen in premenopausal breast cancer patients.
(
- Contribution to journal › Article
- 2005
-
Mark
ERK phosphorylation is linked to VEGFR2 expression and Ets-2 phosphorylation in breast cancer and is associated with tamoxifen treatment resistance and small tumours with good prognosis
(
- Contribution to journal › Article
-
Mark
Tumor-specific expression of vascular endothelial growth factor receptor 2 but not vascular endothelial growth factor or human epidermal growth factor receptor 2 is associated with impaired response to adjuvant tamoxifen in premenopausal breast cancer.
(
- Contribution to journal › Article
-
Mark
Adverse effect of adjuvant tamoxifen in premenopausal breast cancer with cyclin D1 gene amplification.
(
- Contribution to journal › Article
-
Mark
Cyclin I is expressed in human breast cancer and closely associated with VEGF and KDR expression.
(
- Contribution to journal › Article
-
Mark
Pathology parameters and adjuvant tamoxifen response in a randomised premenopausal breast cancer trial.
(
- Contribution to journal › Article